InflaRx Announces Positive Topline Results from the Multiple Ascending Dose (MAD) Phase I Study with C5aR Inhibitor INF904GlobeNewsWire • 01/04/24
After Plunging -17.65% in 4 Weeks, Here's Why the Trend Might Reverse for InflaRx N.V. (IFRX)Zacks Investment Research • 11/28/23
InflaRx N.V. (IFRX) Loses -47.13% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerZacks Investment Research • 11/06/23
InflaRx Announces First Patient Dosed in Phase III Trial with Vilobelimab in Pyoderma GangrenosumGlobeNewsWire • 11/06/23
InflaRx Reports Third Quarter 2023 Financial Results and Provides Business UpdateGlobeNewsWire • 11/01/23
InflaRx Announces Positive Topline Results from the Single Ascending Dose (SAD) Phase I Study with C5aR Inhibitor INF904GlobeNewsWire • 09/11/23
InflaRx's Marketing Authorization Application (MAA) for Vilobelimab for Treatment of Critically Ill COVID-19 Patients under Review by European Medicines Agency (EMA)GlobeNewsWire • 08/30/23
InflaRx Announces Commercial Launch of Gohibic (vilobelimab) in the U.S. for the Treatment of Critically Ill COVID-19 PatientsGlobeNewsWire • 06/21/23
WuXi Biologics Announces Manufacturing Partnership with InflaRx to Advance Gohibic for the Treatment of Certain Critically Ill COVID-19 patientsPRNewsWire • 05/16/23
InflaRx Reports First Quarter 2023 Financial and Operating Results and Provides Business UpdateGlobeNewsWire • 05/11/23
InflaRx Announces Closing of the Full Exercise of Greenshoe Option Increasing the Proceeds of the Recently Announced Public Offering of Ordinary Shares to US$46 millionGlobeNewsWire • 04/18/23
InflaRx shares pop on FDA emergency use authorization of Covid-19 treatment injectionProactive Investors • 04/05/23
InflaRx Receives FDA Emergency Use Authorization for Gohibic (vilobelimab) for Treatment of Critically Ill COVID-19 PatientsGlobeNewsWire • 04/04/23